MarginsXMarginsX
Home › Markets › Health Care › CTXR

Citius Pharmaceuticals Inc. (CTXR)

CTXR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5276
-1.40% on the day
Market cap
$14.5M
Nano cap
Revenue · 2022
$90K
0.0% on 2021
Net income · 2022
-$33.6M
-37378.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2022-09-30, https://www.sec.gov/Archives/edgar/data/1506251/000121390022082217/0001213900-22-082217-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-09-30.

Profile

FieldValue
TickerCTXR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001506251
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2022

LineValue
Revenue$90K
Net income-$33.6M
Operating income-$33.3M
Net margin-37378.5%
Operating margin-37017.8%
Revenue growth0.0%
Cash$41.7M
Total assets$114.0M
P/E (computed)Net income was not positive
P/S (computed)160.9×

Warning signs

Cash runway
5.9 months
$17.0M cash at June 30, 2026
Share count, 1 year
+61.4%
2025-08-11 to 2026-08-13 · +332.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. 6 The Company is currently engaged in capital raising initiatives, as well as separate capital raising initiatives through its s"
10-Q 2026-08-14
Cash and burn$17.0M cash; operating cash flow -$8.7M a quarter.Report 2026-06-30
Shares outstanding27,452,570 (2026-08-13); 17,012,191 a year earlier; 158,857,798 three years earlier. 3y figure adjusted for splits (1-for-25 overall).Cover page 2026-08-13
Reverse splits, 3 years1; latest 1-for-25 on 2024-11-26Source 2024-11-26
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-24
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-21
AuditorWolf & Company, P.C., Boston, Massachusetts, United StatesPCAOB Form AP 2026-01-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
$1.5M-$11.9M-$8.7M$17.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2026-03-31
$1.7M-$28.1M-$1.3M$4.6MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q1 2026
2025-12-31
$3.9M-$9.4M-$13.0M$7.7M$1.0MNeeds four quarters10-Q 2026-02-13
Q4 2025
2025-09-30
Not filed-$8.7M-$11.9M$4.3M$1.0MNeeds four quarters10-K 2025-12-23
Q3 2025
2025-06-30
Not filed-$9.2M-$5.4M$6.1M$1.0MNeeds four quarters10-Q 2026-08-14
Q2 2025
2025-03-31
Not filed-$11.5M-$4.5M$26KNo debt tagsNeeds four quarters10-Q 2025-05-14
Q1 2025
2024-12-31
Not filed-$10.3M-$4.7M$1.1MNo debt tagsNeeds four quarters10-Q 2025-05-14
Q4 2024
2024-09-30
Not filed-$11.1M-$5.9M$3.3MNo debt tagsNeeds four quarters10-K 2025-12-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-32026-05-22
Latest annual report
AMENDMENT NO. 1 TO FORM 10-K
10-K/A2026-01-28
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-08-14
Latest current report
CURRENT REPORT
8-K2026-11-04
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-02-24

Source: SEC EDGAR submissions feed, 638 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.8%
1 month+12.4%
3 months-27.1%
Year to date-31.1%
1 year-47.0%
From 52-week high-62.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier